POS0786 EFFECT OF LORECIVIVINT ON CARTILAGE REPAIR IN A MOUSE MODEL OF JOINT SURFACE INJURY

• Published in: Annals of the rheumatic diseases Vol. 83; no. Suppl 1; p. 652
• Main Authors: Roelofs, A. J., Clark, S. M., Mcclure, J. J., Symons, R. A., Cunningham, I., Robertson, M., Richmond, A., Collins, F. L., Kennedy, S., Tambiah, J. R. S., De Bari, C.
• Format: Journal Article
• Language: English
• Published: Kidlington BMJ Publishing Group Ltd and European League Against Rheumatism 01.06.2024; Elsevier B.V; Elsevier Limited
• Subjects: Alternative splicing; Animal Models; Cartilage; Cartilage diseases; Cdc2 protein; Cell morphology; Disease-modifying Drugs (DMARDs); Dosage; Growth differentiation factor 5; Injection; Knee; Morphology; Osteoarthritis; Phosphorylation; Scientific Abstracts; Statistical analysis; Statistical models; Surgery; Transgenes; Tyrosine; Wnt protein; Wound healing; Cartilage; Animal Models; Disease-modifying Drugs (DMARDs)

Background:Lorecivivint (LOR) is a potential disease-modifying osteoarthritis (OA) drug in clinical development. It is a novel small-molecule inhibitor of Cdc2-Like Kinases (CLKs) and Dual-Specificity Tyrosine Phosphorylation-Regulated Kinases (DYRKs), intra-nuclear kinases involved in alternative s...